M5717 330 mg + PYRONARIDINE for malaria, falciparum

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Jan 2023: Trial registered, NCT05689047
  2. 29 Mar 2023: Trial started, NCT05689047

The trials

NCT05689047: Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)

State
Completed
Phase
Phase 2
People
38 taking part
Started
29 Mar 2023
Primary completion
28 May 2024
Arms
Part A: Safety Run-in Cohort M5717+Pyronaridine
Results
Posted on the registry
  1. 18 Jan 2023: Trial registered
  2. 29 Mar 2023: Trial started
  3. 28 May 2024: Trial completed
  4. 27 Aug 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.